China approves one more Covid-19 vaccine for emergency use

Results support the safety and immunogenicity of this vaccine, with no severe adverse reactions reported

Xinhua March 17, 2021
Medical attendants prepare to vaccinate health workers with Chinese-made Sinopharm Covid-19 vaccine at a vaccination centre in Karachi on February 3. PHOTO: AFP


China has approved the emergency use of a self-developed recombinant protein subunit vaccine against Covid-19, its main developer, the Institute of Microbiology under the Chinese Academy of Sciences, said on Wednesday.

The vaccine (CHO Cells) completed phase-1 and phase-2 clinical trials in October 2020. Results support the safety and immunogenicity of this vaccine, with no severe adverse reactions reported.

Also read: Second batch of Sinopharm vaccines arrive in Islamabad

The level of neutralizing antibody elicited by the vaccine is comparable to other Covid-19 recombinant protein vaccines and mRNA vaccines in the world, according to an institute statement.

Researchers have been holding phase-3 trials since November 2020 in China, Uzbekistan, Pakistan, Ecuador and Indonesia, planning to enroll up to 29,000 adults.

Uzbekistan approved the use of the Chinese vaccine on March 1, and China issued emergency use authorization on March 10.

Recombinant protein subunit vaccine does not need a high-grade biosafety laboratory for manufacture, and can quickly achieve large-scale production. It is more cost-efficient and easier to store and transport, the vaccine maker said.

Jointly developed by the institute and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., the patented vaccine is the world's first Covid-19 recombinant protein subunit vaccine approved for clinical research permit and the fourth Covid-19 vaccine approved for emergency use in China.


Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ


Most Read